Navigation Links
ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
Date:1/30/2009

ATHENS, Ga., Jan. 30 /PRNewswire/ -- ArunA Biomedical, Inc., announced today that it will make its hN2(TM) cells commercially available to the research community in early 2009. The cells, derived from NIH registered human embryonic cell lines, are offered as a normal, consistent population of neural cells in an adherent monolayer format, a product never before offered to the research community. hN2 cells provide a human cell based format for research ranging from Alzheimer's to spinal cord injury and depression.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )

"ArunA has further developed its adherent monolayer technology by creating hN2(TM), a normal human neural cell ideal for drug screening, toxicology studies and basic neural research and we are pleased to be able to offer these cells commercially to the research market," says David Ray, ArunA's Chief Executive Officer. "By offering our products through multi-national distribution partners, we will provide broad access to the unique tools that may accelerate the pace of neural research with more physiologically relevant cellular research models," Ray said.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. The company's first product, hNP1(TM) (ENSTem-A(TM)), is based on patented technology licensed from
'/>"/>

SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
4. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
5. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
6. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
7. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
8. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
9. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
10. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
11. Environmental Tectonics Corporations BioMedical Division Announces New Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... (PRWEB) May 24, 2013 Vestiage, ... lifestyle company focused on science-based research and development, ... anti-aging cosmeceuticals and nutraceuticals, announced today that it ... States for the sale of Reluma Skin Illuminating ... packet and application by sending an email to ...
(Date:5/23/2013)...  BioScrip, Inc. (NASDAQ: BIOS ) today ... 2013 Global Healthcare Conference to be held June 3-6, ... Richard Smith , President and Chief ... Chief Financial Officer, will present on Monday, June 3, ... About BioScrip BioScrip, Inc. provides comprehensive infusion ...
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... and ... convenience, ROCKLAND, ... easypod(R), the first of its kind,automated device in the growth hormone ... origin) for,injection], the company,s treatment for growth hormone deficiency. A 2007,Gold ...
... NEW YORK, Dec. 5 Driven by an aging ... trauma,wound treatment market is expected to post a compound ... by 2011, according to Wound Care Markets,Volume III: Surgical ... With more than 100,000 surgeries performed daily in the ...
... will issue its fourth quarter and fiscal year,2007 financial results on December 11, 2007. ... to discuss the results., December 11, 2007 Schedule:, After ... ... distributed by PR Newswire 4:20 p.m. EST ...
Cached Biology Technology:Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device 2Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device 3Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device 4Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011 2Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007 2Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007 3
(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
(Date:5/23/2013)... suppresses lipid synthesis in the liver, UC Irvine endocrinologists ... liver diseases. , With this finding, Dr. Ellis ... in the field. Study results appear in the May ... , "The dogma in the steroid receptor field for ... the nucleus respond to steroid hormones by regulating genes ...
Breaking Biology News(10 mins):Please do try this at home 2The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
... Haven, Conn.The explosive growth of cities worldwide over the next ... environment, according to a meta-analysis published today in PlosOne. ... that by 2030 urban areas will expand by 590,000 square ... billion more people living in urban areas. "It is ...
... Southampton Centre for Biomedical Research, established by the ... the University of Southampton, have been awarded 17m ... research facilities. The funding, which is ... NHS and university partnerships, has secured the future ...
... agriculture, causing famine and increasing consumer food costs. Now, researchers at the ... completed two drought simulators designed to test the effects of water deficiency ... Research and Extension Center east of Columbia. , , ... , , ...
Cached Biology News:Growth of cities endangers global environment 2Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research 2University of Missouri completes first drought simulator 2University of Missouri completes first drought simulator 3
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... and reliable automation for today's drug ... laboratories. Staccato Mini-Workstations offer the minimal ... liquid handling and material management tasks. ... Caliper's time proven CLARA™ assay development ...
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
... If particles in the submicron range are ... process, measurement and control of particle size ... analyzer that can reliably detect the component ... N5 Submicron Particle Size Analyzer uses Photon ...
Biology Products: